Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Uni-Star under fire as its hit games enter twilight phase
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
